Department of Surgery and the Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):614-8. doi: 10.1158/1055-9965.EPI-09-1080.
Since human papillomavirus (HPV) infection was first identified as a risk factor for cervical cancer, several seroepidemiologic and tissue-based studies have investigated HPV in relation to prostate cancer, another common genitourinary malignancy, with mixed results. To further inform this potential association, we conducted a large, prospective investigation of HPV types 16, 18, and 31 in relation to risk of prostate cancer in the Prostate Cancer Prevention Trial. Cases were a sample of men diagnosed with prostate cancer after visit 2 or on their end-of-study biopsy (n = 616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n = 616). Controls were frequency matched to cases by age, treatment arm, and family history of prostate cancer. Sera from visit 2 were tested for IgG antibodies against HPV types 16, 18, and 31. No associations were observed for weak or strong HPV-16 [odds ratio (OR), 0.94; 95% confidence interval (95% CI), 0.53-1.64 and OR, 1.07; 95% CI, 077-1.48, respectively], HPV-18 (OR, 0.75; 95% CI, 0.27-2.04 and OR, 0.87; 95% CI, 0.47-1.63, respectively), or HPV-31 seropositivity (OR, 0.76; 95% CI, 0.45-1.28 and OR, 1.15; 95% CI, 0.80-1.64, respectively) and risk of prostate cancer. Considering this finding in the context of the HPV and prostate cancer literature, HPV does not appear to be associated with risk of prostate cancer, at least by mechanisms proposed to date, and using epidemiologic designs and laboratory techniques currently available.
自从人乳头瘤病毒（HPV）感染首次被确定为宫颈癌的一个危险因素以来，已有几项血清流行病学和组织学研究调查了 HPV 与前列腺癌之间的关系，前列腺癌是另一种常见的泌尿生殖系统恶性肿瘤，但结果不一。为了进一步阐明这种潜在的关联，我们在前列腺癌预防试验中对 HPV 型 16、18 和 31 与前列腺癌风险的关系进行了一项大型前瞻性调查。病例是在访问 2 或研究结束活检时诊断出患有前列腺癌的男性样本（n=616）。对照组是在试验期间或研究结束活检时未诊断出患有前列腺癌的男性（n=616）。对照组通过年龄、治疗臂和前列腺癌家族史与病例按频率匹配。使用访问 2 的血清检测针对 HPV 型 16、18 和 31 的 IgG 抗体。对于弱或强 HPV-16（比值比[OR]，0.94；95%置信区间[95%CI]，0.53-1.64 和 OR，1.07；95%CI，0.77-1.48），HPV-18（OR，0.75；95%CI，0.27-2.04 和 OR，0.87；95%CI，0.47-1.63）或 HPV-31 血清阳性（OR，0.76；95%CI，0.45-1.28 和 OR，1.15；95%CI，0.80-1.64）与前列腺癌风险之间均未观察到关联。考虑到 HPV 和前列腺癌文献中的这一发现，HPV 似乎与前列腺癌风险无关，至少到目前为止，通过提出的机制，以及使用当前可用的流行病学设计和实验室技术。
